Home

Thursday, May 24, 2018 - 13:52
The ingredients and science behind growth factor-based topicals.By Inga HansenGrowth factor-BASED serums and creams have become ubiquitous in topical antiaging skin care. But what these different products contain can vary widely. Some products contain actual growth factors—either animal- or plant-derived—and others use so-called “signaling” ingredients, typically peptides that trigger the cells in a manner similar to naturally occurring growth factors. In all cases, the goal is to combat the changes that occur in aging skin
https://www.medestheticsmag.com/restoring-growth
Thursday, May 24, 2018 - 13:52
The ingredients and science behind growth factor-based topicals.By Inga HansenGrowth factor-BASED serums and creams have become ubiquitous in topical antiaging skin care. But what these different products contain can vary widely. Some products contain actual growth factors—either animal- or plant-derived—and others use so-called “signaling” ingredients, typically peptides that trigger the cells in a manner similar to naturally occurring growth factors. In all cases, the goal is to combat the changes that occur in aging skin
https://www.medestheticsmag.com/restoring-growth
Thursday, May 24, 2018 - 13:36
The U.S. Food and Drug Administration (FDA) has approved the hyaluronic acid (HA) dermal filler Restylane Lyft (Nestlé Skin Health) for the correction of age-related volume loss in the back of the hands for patients over the age of 21. It is the first HA injectable gel to be FDA-approved for restoring fullness to the back of the hands.
https://www.medestheticsmag.com/restylane-lyft-approved-hands

Advertisement - Box 1

Advertisement - Box 2

Thursday, May 24, 2018 - 13:36
The U.S. Food and Drug Administration (FDA) has approved the hyaluronic acid (HA) dermal filler Restylane Lyft (Nestlé Skin Health) for the correction of age-related volume loss in the back of the hands for patients over the age of 21. It is the first HA injectable gel to be FDA-approved for restoring fullness to the back of the hands.
https://www.medestheticsmag.com/restylane-lyft-approved-hands
Thursday, May 24, 2018 - 13:32
Revance Therapeutics has established four new positions at the company as it prepares for the launch and commercialization of its daxibotulinumtoxinA injectable (RT002) for the treatment of glabellar lines.
https://www.medestheticsmag.com/revance-gears-launch-rt002-neurotoxin
Thursday, May 24, 2018 - 13:32
Revance Therapeutics has established four new positions at the company as it prepares for the launch and commercialization of its daxibotulinumtoxinA injectable (RT002) for the treatment of glabellar lines.
https://www.medestheticsmag.com/revance-gears-launch-rt002-neurotoxin

Advertisement - Box 3

Advertisement - Box 4

Thursday, May 17, 2018 - 12:27
ALASTIN Skincare has appointed James P. Hartman to the position of chief commercial officer. Hartman most recently served as vice president and general manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Solta, he was VP and U.S. head of aesthetics & OTC at Merz Aesthetics and VP of global marketing and business development at Obagi Medical.
https://www.medestheticsmag.com/hartman-named-chief-commercial-officer-alastin
Thursday, May 17, 2018 - 12:27
ALASTIN Skincare has appointed James P. Hartman to the position of chief commercial officer. Hartman most recently served as vice president and general manager at Solta Medical, a division of Valeant Pharmaceuticals. Prior to Solta, he was VP and U.S. head of aesthetics & OTC at Merz Aesthetics and VP of global marketing and business development at Obagi Medical.
https://www.medestheticsmag.com/hartman-named-chief-commercial-officer-alastin
Thursday, May 17, 2018 - 12:25
The approval of Evolus’ DWP-450 (prabotulinumtoxinA) has hit a snag, reportedly due to issues at the appointed manufacturing facility. The U.S. Food & Drug Administration issued a complete response letter (CRL) to the company’s biologic license application for DWP-450 outlining concerns that must be addressed before the FDA can approve the new neurotoxin for marketing in the U.S.
https://www.medestheticsmag.com/evolus-vows-move-forward-fda-fails-approve-its-neurotoxin

Pages

Advertisement - Box 5

Advertisement - Box 6